Iris M. Seignette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iris M. Seignette has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Lodewyk F. A. Wessels
The Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Annegien Broeks
Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands
35 shared publications - Erik Hooijberg
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
35 shared publications - Alberto Gil-Jimenez
Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands
24 shared publications - Daniel J. Vis
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital 5 Department of Molecular Carcinogenesis Amsterdam, the Netherlands
24 shared publications - Michiel S. van der Heijden
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
24 shared publications
Latest Publications
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- Open Access
A spatial single-cell transcriptomic atlas of metastatic breast cancer progression
Metastatic breast cancer represents a major societal burden and is a main cause of cancer-related death in women, with limited rationale-based treatment options and often dismal outcomes. Intra-tumor heterogeneity, tumor-stromal interactions and clonal selection are considered to play a major role in metastasis formation and disease progression, but these processes remain incompletely understood. Leveraging spatial transcriptomics as cost-effective method for generating transcriptomics data at single-cell resolution, we present a single-cell spatial transcriptomics atlas of 126 tumor samples from 44 metastatic breast cancer patients, encompassing 520,850 cells from primary and metastatic lesions, with 171,766 cancer cells and 349,084 cells belonging to the tumor microenvironment. For most patients, multiple time-points of sample collection throughout metastatic disease progression were analyzed, allowing for detection of treatment-induced transcriptional changes driving therapy resistance within the tumor cell compartment. Distinct immune cell subpopulations were enriched upon progression following specific therapeutics and were predictive for hormone receptor loss. By inferring DNA copy number alterations from the single-cell transcriptomics data, we tracked subclonal tumor cell selection upon progression and identified critical transcriptomic features of outcompeting clones with future metastatic potential. Cumulatively, we present a unique single-cell spatial framework on metastatic breast cancer development and progression, in a highly complex systemic treatment landscape.
Open AccessA spatial single-cell transcriptomic atlas of metastatic breast cancer progression
Metastatic breast cancer represents a major societal burden and is a main cause of cancer-related death in women, with limited rationale-based treatment options and often dismal outcomes. Intra-tumor heterogeneity, tumor-stromal interactions and clonal selection are considered to play a major role in metastasis formation and disease progression, but these processes remain incompletely understood. Leveraging spatial transcriptomics as cost-effective method for generating transcriptomics data at single-cell resolution, we present a single-cell spatial transcriptomics atlas of 126 tumor samples from 44 metastatic breast cancer patients, encompassing 520,850 cells from primary and metastatic lesions, with 171,766 cancer cells and 349,084 cells belonging to the tumor microenvironment. For most patients, multiple time-points of sample collection throughout metastatic disease progression were analyzed, allowing for detection of treatment-induced transcriptional changes driving therapy resistance within the tumor cell compartment. Distinct immune cell subpopulations were enriched upon progression following specific therapeutics and were predictive for hormone receptor loss. By inferring DNA copy number alterations from the single-cell transcriptomics data, we tracked subclonal tumor cell selection upon progression and identified critical transcriptomic features of outcompeting clones with future metastatic potential. Cumulatively, we present a unique single-cell spatial framework on metastatic breast cancer development and progression, in a highly complex systemic treatment landscape.
- Open Access
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8096) , 467-476
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
Emerging evidence suggests a correlation between CD8 + T cell–tumour cell proximity and anti-tumour immune response 1,2 . However, it remains unclear whether these cells exist as functional clusters that can be isolated from clinical samples. Here, using conventional and imaging flow cytometry, we show that from 21 out of 21 human melanoma metastases, we could isolate heterotypic clusters, comprising CD8 + T cells interacting with one or more tumour cells and/or antigen-presenting cells (APCs). Single-cell RNA-sequencing analysis revealed that T cells from clusters were enriched for gene signatures associated with tumour reactivity and exhaustion. Clustered T cells exhibited increased TCR clonality indicative of expansion, whereas TCR-matched T cells showed more exhaustion and co-modulation when conjugated to APCs than when conjugated to tumour cells. T cells that were expanded from clusters ex vivo exerted on average ninefold increased killing activity towards autologous melanomas, which was accompanied by enhanced cytokine production. After adoptive cell transfer into mice, T cells from clusters showed improved patient-derived melanoma control, which was associated with increased T cell infiltration and activation. Together, these results demonstrate that tumour-reactive CD8 + T cells are enriched in functional clusters with tumour cells and/or APCs and that they can be isolated and expanded from clinical samples. Typically excluded by single-cell gating in flow cytometry, these distinct heterotypic T cell clusters are a valuable source to decipher functional tumour–immune cell interactions and may also be therapeutically explored.
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8096) , 467-476
Open AccessTumour-reactive heterotypic CD8 T cell clusters from clinical samples
Emerging evidence suggests a correlation between CD8 + T cell–tumour cell proximity and anti-tumour immune response 1,2 . However, it remains unclear whether these cells exist as functional clusters that can be isolated from clinical samples. Here, using conventional and imaging flow cytometry, we show that from 21 out of 21 human melanoma metastases, we could isolate heterotypic clusters, comprising CD8 + T cells interacting with one or more tumour cells and/or antigen-presenting cells (APCs). Single-cell RNA-sequencing analysis revealed that T cells from clusters were enriched for gene signatures associated with tumour reactivity and exhaustion. Clustered T cells exhibited increased TCR clonality indicative of expansion, whereas TCR-matched T cells showed more exhaustion and co-modulation when conjugated to APCs than when conjugated to tumour cells. T cells that were expanded from clusters ex vivo exerted on average ninefold increased killing activity towards autologous melanomas, which was accompanied by enhanced cytokine production. After adoptive cell transfer into mice, T cells from clusters showed improved patient-derived melanoma control, which was associated with increased T cell infiltration and activation. Together, these results demonstrate that tumour-reactive CD8 + T cells are enriched in functional clusters with tumour cells and/or APCs and that they can be isolated and expanded from clinical samples. Typically excluded by single-cell gating in flow cytometry, these distinct heterotypic T cell clusters are a valuable source to decipher functional tumour–immune cell interactions and may also be therapeutically explored.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
The NABUCCO treatment regimens for cohort 1, 2A and 2B. Cohort 1 was the initial cohort. Later in time, cohort 2 was initiated, in which patients were randomized to cohort 2A (ipilimumab-high) or cohort 2B (ipilimumab-low). Before treatment initiation, tumor tissue was obtained during a transurethral resection of the tumor (lower tract tumors) or via a biopsy (upper tract tumors).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
The NABUCCO treatment regimens for cohort 1, 2A and 2B. Cohort 1 was the initial cohort. Later in time, cohort 2 was initiated, in which patients were randomized to cohort 2A (ipilimumab-high) or cohort 2B (ipilimumab-low). Before treatment initiation, tumor tissue was obtained during a transurethral resection of the tumor (lower tract tumors) or via a biopsy (upper tract tumors).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Patient fractions per molecular subtype for response groups a. Fraction of patients per molecular subtype (n=5) according to the consensus classification. b. Fraction of patients per molecular subtype (n=4) according to the TCGA classification. There were no neuro-endocrine subtypes in our patient cohort. Responders (<=ypT1N0) are depicted in blue, non-responders (ypT2-4aNx or ypTxN1-3) are depicted in orange.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Patient fractions per molecular subtype for response groups a. Fraction of patients per molecular subtype (n=5) according to the consensus classification. b. Fraction of patients per molecular subtype (n=4) according to the TCGA classification. There were no neuro-endocrine subtypes in our patient cohort. Responders (<=ypT1N0) are depicted in blue, non-responders (ypT2-4aNx or ypTxN1-3) are depicted in orange.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Consort diagram of available samples per analysis for each arm at baseline and on-treatment. One patient in arm 2A and 3 patients in arm 2B did not undergo cystectomy.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Consort diagram of available samples per analysis for each arm at baseline and on-treatment. One patient in arm 2A and 3 patients in arm 2B did not undergo cystectomy.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Details about methods used for mIF, DNA- and RNA isolation and sequencing and single-cell RNA sequencing
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Details about methods used for mIF, DNA- and RNA isolation and sequencing and single-cell RNA sequencing